KR20240099430A - 항체 분자 및 접합체 - Google Patents
항체 분자 및 접합체 Download PDFInfo
- Publication number
- KR20240099430A KR20240099430A KR1020247018705A KR20247018705A KR20240099430A KR 20240099430 A KR20240099430 A KR 20240099430A KR 1020247018705 A KR1020247018705 A KR 1020247018705A KR 20247018705 A KR20247018705 A KR 20247018705A KR 20240099430 A KR20240099430 A KR 20240099430A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- seq
- region
- egfr
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263835P | 2021-11-10 | 2021-11-10 | |
| US63/263,835 | 2021-11-10 | ||
| PCT/EP2022/081225 WO2023083846A1 (en) | 2021-11-10 | 2022-11-09 | Antibody molecules and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240099430A true KR20240099430A (ko) | 2024-06-28 |
Family
ID=84387847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247018705A Pending KR20240099430A (ko) | 2021-11-10 | 2022-11-09 | 항체 분자 및 접합체 |
Country Status (15)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025525410A (ja) * | 2022-06-27 | 2025-08-05 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ |
| CN122161833A (zh) * | 2023-11-15 | 2026-06-05 | 四川科伦博泰生物医药股份有限公司 | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| IL328594A (en) | 2023-11-23 | 2026-07-01 | Velavigo Bio Inc | Binding molecule and antibody-drug conjugate and their uses |
| CN117659203B (zh) * | 2023-12-06 | 2024-08-13 | 科弈(浙江)药业科技有限公司 | 一种抗met/egfr双特异性抗体及其药物偶联物 |
| WO2025148868A1 (zh) | 2024-01-08 | 2025-07-17 | 泰励生物科技(上海)有限公司 | 一种抗体偶联药物及其用途 |
| TW202608928A (zh) * | 2024-04-30 | 2026-03-01 | 荷蘭商美勒斯公司 | 多特異性抗體藥物偶聯物 |
| TW202608927A (zh) * | 2024-04-30 | 2026-03-01 | 荷蘭商美勒斯公司 | 多特異性抗體-藥物偶聯物 |
| WO2026021476A1 (en) | 2024-07-24 | 2026-01-29 | Beone Guangzhou Biologics Manufacturing Co., Ltd. | Anti-cmet and anti-egfr multispecific antibody drug conjugates |
| CN121868507A (zh) * | 2024-10-16 | 2026-04-17 | 上海安领科生物医药有限公司 | 抗EGFR和cMET双特异性抗体的抗体药物偶联物 |
| WO2026086737A1 (en) | 2024-10-21 | 2026-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases |
| WO2026086740A1 (en) | 2024-10-21 | 2026-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Use and method of bispecific antibody-drug conjugates for treating tumor diseases |
| WO2026086844A1 (zh) * | 2024-10-23 | 2026-04-30 | 正大天晴药业集团股份有限公司 | 靶向EGFR和c-Met的抗体药物偶联物 |
| WO2026098440A1 (zh) * | 2024-11-05 | 2026-05-15 | 上海齐鲁制药研究中心有限公司 | 一种双特异性抗体偶联物及其制备方法和应用 |
| WO2026124468A1 (en) * | 2024-12-10 | 2026-06-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Pharmaceutical combinations, their uses and therapeutic methods |
| WO2026145588A1 (en) | 2024-12-31 | 2026-07-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Use of egfr/c-met bispecific binding protein |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026150367A1 (en) * | 2025-01-13 | 2026-07-16 | Janssen Biotech, Inc. | Bispecific anti-egfr/c-met antibody-drug conjugates |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP1521769B1 (de) | 2002-07-09 | 2015-09-09 | Dömling, Alexander | Tubulysinkonjugate |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| US8889880B2 (en) | 2010-08-06 | 2014-11-18 | Endocyte, Inc. | Processes for preparing tubulysins |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR102089591B1 (ko) | 2013-07-29 | 2020-03-18 | 삼성전자주식회사 | 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체 |
| CA2945318A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Tubulysin derivatives |
| JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
| EP3630844A4 (en) | 2017-05-30 | 2021-03-03 | Chong Kun Dang Pharmaceutical Corp. | NOVEL ANTI-C-MET ANTIBODY AND USE OF IT |
-
2022
- 2022-11-09 KR KR1020247018705A patent/KR20240099430A/ko active Pending
- 2022-11-09 MX MX2024005712A patent/MX2024005712A/es unknown
- 2022-11-09 WO PCT/EP2022/081225 patent/WO2023083846A1/en not_active Ceased
- 2022-11-09 EP EP22817545.1A patent/EP4429765A1/en active Pending
- 2022-11-09 CN CN202280086269.9A patent/CN118556084A/zh active Pending
- 2022-11-09 CA CA3237211A patent/CA3237211A1/en active Pending
- 2022-11-09 US US18/053,955 patent/US12065496B2/en active Active
- 2022-11-09 IL IL312566A patent/IL312566A/en unknown
- 2022-11-09 JP JP2024527384A patent/JP7861115B2/ja active Active
- 2022-11-09 AU AU2022384597A patent/AU2022384597B2/en active Active
- 2022-11-10 AR ARP220103086A patent/AR127629A1/es unknown
- 2022-11-10 TW TW111143063A patent/TW202336037A/zh unknown
-
2024
- 2024-05-08 CL CL2024001384A patent/CL2024001384A1/es unknown
- 2024-06-07 EC ECSENADI202444371A patent/ECSP24044371A/es unknown
- 2024-06-07 CO CONC2024/0007192A patent/CO2024007192A2/es unknown
- 2024-06-25 US US18/753,316 patent/US20240360226A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022384597B2 (en) | 2026-05-07 |
| ECSP24044371A (es) | 2024-07-31 |
| JP7861115B2 (ja) | 2026-05-18 |
| US12065496B2 (en) | 2024-08-20 |
| WO2023083846A1 (en) | 2023-05-19 |
| IL312566A (en) | 2024-07-01 |
| US20230183358A1 (en) | 2023-06-15 |
| EP4429765A1 (en) | 2024-09-18 |
| CL2024001384A1 (es) | 2024-08-23 |
| CN118556084A (zh) | 2024-08-27 |
| JP2024544520A (ja) | 2024-12-03 |
| US20240360226A1 (en) | 2024-10-31 |
| TW202336037A (zh) | 2023-09-16 |
| AU2022384597A1 (en) | 2024-06-13 |
| MX2024005712A (es) | 2024-05-24 |
| AR127629A1 (es) | 2024-02-14 |
| CA3237211A1 (en) | 2023-05-19 |
| CO2024007192A2 (es) | 2024-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022384597B2 (en) | Antibody molecules and conjugates | |
| JP7118117B2 (ja) | 抗体-薬物コンジュゲートの選択的製造方法 | |
| JP6449366B2 (ja) | 抗trop2抗体−薬物コンジュゲート | |
| JP7767411B2 (ja) | 抗fgfr2抗体及びその使用方法 | |
| CA3005294A1 (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| JP2021521872A (ja) | C−metに特異的に結合する抗体及びその用途 | |
| KR20250029133A (ko) | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 | |
| WO2026086740A1 (en) | Use and method of bispecific antibody-drug conjugates for treating tumor diseases | |
| WO2025242845A1 (en) | Colorectal cancer treatment | |
| TW202543685A (zh) | 抗體藥物偶聯物及其製備方法和用途 | |
| WO2026098440A1 (zh) | 一种双特异性抗体偶联物及其制备方法和应用 | |
| HK40086745A (en) | Method for selectively manufacturing antibody-drug conjugate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |